Herbas VPB

Print
EN | LT
LT - COMBINED USE OF ANTI PD-1 AND ANTI M-CSF ANTIBODIES IN THE TREATMENT OF CANCER
EN - COMBINED USE OF ANTI PD-1 AND ANTI M-CSF ANTIBODIES IN THE TREATMENT OF CANCER

Legal status

Patent not validated

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. C07K 16/28 (2006.01)
A61P 35/00 (2006.01)
C07K 16/24 (2006.01)
A61K 39/395 (2006.01)
European patent
(11) Number of the document 3328425
(13) Kind of document T
(96) European patent application number 16750495.0
Date of filing the European patent application 2016-07-27
(97) Date of publication of the European application 2018-06-06
(45) Date of publication and mention of the grant of the patent 2021-08-25
(46) Date of publication of the claims translation
PCT application
(86) Number PCT/IB2016/054487
Date 2016-07-27
PCT application publication
(87) Number WO 2017/017623
Date 2017-02-02
Priority applications
(30) Number Date Country code
201562198384 P 2015-07-29 US
201662352637 P 2016-06-21 US
Inventors
(72)
FJAELLSKOG, Marie-Louise , US
CAMERON, John , US
CAO, Zhu , US
CIPOLLETTA, Daniela , US
MACISAAC, Kenzie , US
Grantee
(73) Novartis AG , Lichtstrasse 35, 4056 Basel, CH
Title
(54) COMBINED USE OF ANTI PD-1 AND ANTI M-CSF ANTIBODIES IN THE TREATMENT OF CANCER
  COMBINED USE OF ANTI PD-1 AND ANTI M-CSF ANTIBODIES IN THE TREATMENT OF CANCER